

Dr. Henning Gädeke, Chair of the Global Health EDCTP3 Joint Undertaking Governing Board  
c/o Dr. Michael Makanga, Global Health EDCTP3 Joint Undertaking Executive Director  
Global Health EDCTP3 Joint Undertaking  
56 – 60 Avenue de la Toison d'Or  
1060 Brussels  
Belgium

September 29, 2025

## Letter of endorsement

Dear Sir/Madam,

On behalf of Good Ventures Foundation, 314 Lytton Ave. Palo Alto, CA 94301 and in accordance with Council Regulation (EU) No 2085/2021 of 19<sup>th</sup> November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

Good Ventures Foundation (“GVF”) is a California nonprofit public benefit corporation and a tax-exempt private foundation as described in Section 501(c)(3) of the United States Internal Revenue Code. The mission of GVF is to help humanity thrive. Good Ventures Foundation is supported by Open Philanthropy Project LLC for grants management services.

In keeping with its mission to help humanity thrive, GVF seeks to support the research and development of treatments for diseases that disproportionately impact millions of people in low- and middle-income countries. In furthering this goal, GVF intends to support the clinical development of existing and new antimalarial candidates.

GVF is pleased to confirm its intention, pending any final due diligence, to join as a contributing partner to the Global Health EDCTP3 Joint Undertaking, in alignment with its mandate to support high-impact interventions against major infectious diseases of poverty. Our contribution to the Targeting school-Age Children for malaria Transmission Interruption at Community level (TACTIC) project represents a direct financial contribution (FC) designed to complement and reinforce Global Health EDCTP3 JU objectives. By providing sustained support over the course of the four-year project, we believe our grant will help strengthen the evidence base for expanded and enhanced chemoprevention strategies in school-age children—an underserved but critical population for malaria transmission in sub-Saharan Africa. In addition, our role as a backstopping funder for U.S. NIH support will ensure continuity of project activities despite funding uncertainties, thereby safeguarding progress towards the JU’s goals of reducing malaria morbidity, mortality, and transmission.

This contribution is directly aligned with the Global Health EDCTP3 JU call HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage, which seeks to advance late-stage clinical trials of novel or improved malaria interventions. TACTIC will generate pivotal data on the effectiveness of extended seasonal malaria chemoprevention (with and without transmission-blocking primaquine) in Burkina Faso, and intermittent preventive treatment in school children in Uganda, thereby addressing the expected outcomes 1, 3, and 4 of the call. The evidence generated will support WHO

guideline development, national malaria policy adoption, and deployment of innovative chemoprevention strategies across Africa

Specifics of proposed involvement (project areas, work packages, deliverables, topics/entities to be funded):

- GVFs support will directly enable and safeguard delivery of core trial activities and all cross-cutting work packages. This includes all activities that are not directly supported by other sources of funding or in kind support, and any items that may be ineligible for direct EDCTP funds.

Our contribution will also provide resilience to the project's funding base by underwriting up to EUR 1.65 million of NIH support to UCSF/IDRC under the CRITICAL award, thereby reducing risks posed by the volatile U.S. funding environment and ensuring the project's planned scope can be maintained

We estimate the total value of GVF's contribution to be EUR **3.9** million as a direct financial commitment. This sum is represented in our budget as *financial* contributions to LSHTM, LSTM and GRAS. This commitment comes in addition to a preaward (422k EUR) made to LSHTM in August 2025 to initiate baseline trial activities for the Burkina Faso trial, which has enabled development of the proposal and funds activities prior to the study start; this amount is not leveraged in our budgets. In addition, GVF intends to agree to backstop EUR 1.65 million of current NIH support (3.97m own-resources of IDRC) through a financial contribution made directly to LSHTM, in the event that IDRCs NIH co-funding becomes unavailable in the later years of the project. This estimate corresponds to a financial contribution that would be paid over the four-year duration of the project in accordance with the project financial requirements. This backstop cannot be represented in the TACTIC budgets (other than to state that it would replace 1.65m or the 3.97m IDRC 'own resources'), and is intended only as an insurance against unforeseeable retraction of financial commitments by other partners. All contributions from GVF are provided as direct financial support; no in-kind contributions are anticipated.

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. Internal dissemination of information within our organisation, our affiliates, and our advisors will be done on the basis of the "need-to-know" principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.

4. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Sincerely,

Signed by:  
*Sarah Li*  
E0F15876A076478...

Sarah Li  
Authorized Signatory